Ponatinib: all 57 studies that test it

Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/LymphomaRecruitingNCT07224100Phase 2
• Using Tumor Models to Determine TreatmentsRecruitingNCT06813079Phase 2
• A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)RecruitingNCT06207123Phase 1/2
• Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCTRecruitingNCT06061094Phase 2
• Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)RecruitingNCT04747912Phase 2
• Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid LeukemiaNot yet recruitingNCT04709731Phase 2
• Study in Adult Ph-positive ALLNot yet recruitingNCT04688983Phase 2
• Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsRecruitingNCT03934372Phase 1/2
• Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaRecruitingNCT03739814Phase 2
• Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaRecruitingNCT03263572Phase 2
• Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibRecruitingNCT01746836Phase 2
• A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaTerminatedNCT04501614Phase 1/2Results posted
• Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung CancerCompletedNCT03704688Phase 1/2Results posted
• A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic LeukemiaActive, not recruitingNCT03589326Phase 3Results posted
• Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaTerminatedNCT03576547Phase 1/2Results posted
• A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid LeukemiaTerminatedNCT02627677Phase 3Results posted
• Trial of Ponatinib in Patients With Bevacizumab-Refractory GlioblastomaCompletedNCT02478164Phase 2Results posted
• Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of DosesCompletedNCT02467270Phase 2Results posted
• Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.CompletedNCT02272998Phase 2Results posted
• Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 FusionsCompletedNCT02265341Phase 2Results posted
• Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive BiomarkersCompletedNCT01935336Phase 2Results posted
• A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorCompletedNCT01874665Phase 2Results posted
• Ponatinib for Advanced Medullary Thyroid CancerTerminatedNCT01838642Phase 2Results posted
• Ponatinib in Advanced NSCLC w/ RET TranslocationsCompletedNCT01813734Phase 2Results posted
• Ponatinib for Squamous Cell Lung and Head and Neck CancersTerminatedNCT01761747Phase 2/3Results posted
• A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01667133Phase 1/2Results posted
• Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)TerminatedNCT01650805Phase 3Results posted
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
• Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)TerminatedNCT01570868Phase 2Results posted
• Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01207440Phase 2Results posted
• Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia PatientsActive, not recruitingNCT05306301Phase 2
• A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaTerminatedNCT05268003Phase 2
• Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaWithdrawnNCT04845035Phase 2
• Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingNCT04722848Phase 3
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALLTerminatedNCT04554459Phase 2
• Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological RelapseActive, not recruitingNCT04475731Phase 2
• The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I MutationCompletedNCT04233346Phase 2
• Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT04188405Phase 2
• Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)CompletedNCT04160546Phase 2
• Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseActive, not recruitingNCT04070443Phase 2
• Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid LeukemiaStatus unknownNCT04043676Phase 2
• PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISISCompletedNCT03895671Phase 2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Ponatinib in Advanced or Metastatic Medullary Thyroid CancerWithdrawnNCT03838692Phase 2
• Study in Patients With Chronic LeukemiaTerminatedNCT03807479Phase 2
• Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML PatientsCompletedNCT03690115Phase 2
• POETIG Trial - POnatinib After rEsisTance to Imatinib in GISTStatus unknownNCT03171389Phase 2
• Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaActive, not recruitingNCT03147612Phase 2
• Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)WithdrawnNCT02829840Phase 1/2
• Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic LeukemiaStatus unknownNCT02776605Phase 2
• Ponatinib for FLT3-ITD Acute Myelogenous LeukemiaCompletedNCT02428543Phase 1/2
• Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to ImatinibTerminatedNCT02398825Phase 2
• Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial CarcinomaWithdrawnNCT01888562Not applicable
• Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.CompletedNCT01641107Phase 2
• Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaActive, not recruitingNCT01424982Phase 2
• Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological MalignanciesCompletedNCT00660920Phase 1

← Ponatinib overview